Kailera Therapeutics, Inc. Payments for Repurchase of Initial Public Offering
Kailera Therapeutics, Inc. (KLRA) reported Payments for Repurchase of Initial Public Offering of $3.04 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2026-05-26
- Kailera Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2026-03-31 was $3.04M.
- Kailera Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2025-03-31 was $0.00.
| Period end | Payments for Repurchase of Initial Public Offering 3 month |
|---|---|
| 2026-03-31 | $3.04M 10-Q · filed 2026-05-26 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |